Impact of Chronic Thrombocytopenia on In-Hospital Outcomes After Percutaneous Coronary Intervention
Karam Ayoub(University of Kentucky), Srikanth Vallurupalli, Ahmed Abdel‐Latif(University of Kentucky), Khaled M. Ziada(Cleveland Clinic), Meera Marji(University of Kentucky), Ahmad Masri(Oregon Health & Science University), Gbolahan Ogunbayo(University of Kentucky)
Cited by 41
Related Papers
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet|2020|1.2k
Extent and Direction of Arterial Remodeling in Stable Versus Unstable Coronary Syndromes
|Circulation|2000|751
High Prevalence of Coronary Atherosclerosis in Asymptomatic Teenagers and Young Adults
|Circulation|2001|681
Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy
|New England Journal of Medicine|2024|453